PROFILE OF THE SAFETY OF ANTITUBERCULOUS MEDICINES AGAINST THE BACKGROUND OF THE PHARMACOTHERAPY OF PULMONARY TUBERCULOSIS
DOI:
https://doi.org/10.11603/2415-8798.2018.1.8761Keywords:
tuberculosis, antituberculosis drugs (AT ВDs), side reactions (SR).Abstract
Despite the tendency towards stabilization of tuberculosis rates and mortality from this disease, the epidemiological situation of TB in Ukraine is unsustainable. Conducting of full chemotherapy, especially when standard courses are used, may be limited by the development of side reactions (SR ) of antituberculosis drugs (ATBD s), that requires from the physician the continuously evaluating of the risk, benefit and risk, the relationship between risk and benefit in administering ATBD s, monitoring SR , prevention and treatment in order to minimize deviations from standard circuits of chemotherapy taking into account the serious consequences of tuberculosis for both the patient and the community.
The aim of the study – to learn the safety profile of AT ВDs, as well as the study, analysis and generalization of information on the side effect of anti-TB drugs on the basis of monitoring in Mykolaiv and the region in 2016.
Results and Discussion. The taken analysis of the cases of drug abuse showed that among 912 card-reports on the complication of pharmacotherapy, 314 reports related to AT ВDs, which amounted to 34.4 % from the total number of cases of adverse drug reactions. The overwhelming majority of cases of complications of AT ВD registered in the region are the expected reactions in the form of a violation of the function of the gastrointestinal tract (38 %), the musculoskeletal system (19 %), allergic skin and its derivatives (15 %) and ototoxicity (10 %). At the same time, in 86.6 % of cases medication correction is necessary for drug replacement, and 20.1 % of patients need to cancel the suspect drug. It was found that manifestations of SR appeared in adult male patients (63.4 %) at the age of 31–45 years (44.8 %) with antituberculous therapy during the first 15 days (54.2 %). The drugs "leaders" in terms of the emergence of SR are: pyrazinamide (24.5 %), protionamide (17.2 %) and ethionamide (13.7 %).
Conclusions. The results of the presented analysis underline the severity of the problem of complications of antituberculous therapy and the need to develop adequate methods for their pharmacological correction, which will help to reduce the cessation of chemotherapy, improve its effectiveness and promote adherence to the treatment of this category of patients.
References
Veselovskyi, L.V. (2017). Smertnist vid tuberkulozu lehen v Ukraini, yii dynamika, struktura ta rehionalni osoblyvosti do i pid chas epidemii [Mortality from pulmonary tuberculosis in Ukraine, its dynamics, structure and regional peculiarities before and during the epidemic]. Tuberkuloz, lehenevi khvoroby, VIL–infektsiia – Tuberculosis, pulmonary diseases, HIV-infection, 1 (28), 97-103 [in Ukrainian].
(2017). Ezhenedelnyk Apteka «Borotba z tuberkulozom : chy ye uspikhy v Ukrayini» [Weekly Pharmacy "Fighting TB: Are There Advances in Ukraine?"]. Retrieved from: http://www.apteka.ua/article/405333.
Nizova, N.M. Pavlova, O.V. & Shcherbinska, A.M. (2015). Tuberkuloz v Ukrayini : analitychno-statystychnyy dovidnyk MOZ Ukrayiny [Tuberculosis in Ukraine: analytical and statistical directory of the Ministry of Health of Ukraine]. K. : Blank–Pres, 116 [in Ukrainian].
Petrenko, V.I. & Protsyuk R.H. (2015). Problema tuberkulozu v Ukrayini [The problem of tuberculosis in Ukraine]. Tuberkuloz, lehenevi khvoroby, VIL–infektsiia – Tuberculosis, pulmonary diseases, HIV-infection, 2 (21), 16-29 [in Ukrainian].
Prosvyetov, Yu.V. (2000). Uskladnennia vnaslidok zastosuvannia likarskykh preparativ pry khimioterapii khvorykh na tuberkuloz yak problema ftyziatrii [Complications due to the use of drugs in chemotherapy of patients with tuberculosis as a problem of phthisiology]. Ukrayinskyi khimioterapevtychnyi zhurnal – Ukrainian chemo-therapeutic journal, 2, 44-46 [in Ukrainian].
Pukhlyk, B.M. (2011). Pobichna diia likarskykh zasobiv u ftyziatrychnii praktytsi [The Side Effect of Drugs in Phthisiological Practice]. Tuberkuloz, lehenevi khvoroby, VIL–infektsiia – Tuberculosis, pulmonary diseases, HIV-infection, 1 (4), 20-27 [in Ukrainian].
Feshchenko, Yu.I. (2011). Otsinka kontroliu za tuberkulozom v Ukraini za period 2006-2010 roky [Estimation of TB control in Ukraine for the period of 2006 - 2010]. Ukrayinskyi pulmonolohichnyi zhurnal – Ukrainian pulmonological journal, 4, 5-10 [in Ukrainian].
Feshchenko, Yu.I., Lytvynenko, N.A., Pronyk, L.M. & Pohrebna, M.V. (2017). Vedennia pobichnykh reaktsiy pid chas likuvannia khvorykh na tuberkuloz ta ko–infektsiiu (tuberkuloz/VIL–infektsiya/SNID) [Conducting of adverse reactions in treatment of patients with tuberculosis and co-infection (tuberculosis / HIV / AIDS)]. Tuberkuloz, lehenevi khvoroby, VIL–infektsiia – Tuberculosis, pulmonary diseases, HIV-infection, 4 (31),13-24 [in Ukrainian].
Feshchenko, Yu.I., Cherenko, S.O., Matvyeyeva, O.V., Yaychenya, V.P. & Lohvyna, I.O. (2014.). Pobichni reaktsii protytuberkuloznykh preparativ pry otsintsi likuvannia tuberkulozu [Adverse reactions of anti-TB drugs in the evaluation of tuberculosis treatment]. Tuberkuloz, lehenevi khvoroby, VIL–infektsiia – Tuberculosis, pulmonary diseases, HIV-infection, 4 (19), 13-20 [in Ukrainian].
Feshchenko, Yu.I. (2008). Reiestratsiia pobichnykh reaktsii protytuberkuloznykh preparativ pry likuvanni khvorykh na tuberkuloz. Ukrainskyi pulmonolohichnyi zhurnal – Ukrainian pulmonologist journal, 4, 8-13 [in Ukrainian].
Cherenko, S.O., Lyepshyna, S.M., Matvyeyeva, O.V., Yaychenya, V.P. & Lohvyna, I.O. (2014). Pobichni reaktsii protytuberkuloznykh preparativ pry otsintsi likuvannia tuberkulozu. Novyny medytsyny ta farmatsii – News of Medicine and Pharmacy, 13-14, 16-21 [in Ukrainian].
Downloads
Published
How to Cite
Issue
Section
License
Authors who sent their manuscript to "Вісник наукових досліджень. Bulletin of Scientific Research" Surgery agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. 
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
